Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.

British journal of haematology·2026

Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026

Same author

Association Between Transfusion Status, Hemoglobin Levels, and Patient-Reported Outcomes in Myelofibrosis: A Post Hoc Clinical Trial Analysis.

Cancer medicine·2026

Same author

Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction.

Expert opinion on pharmacotherapy·2026

Same author

Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit control.

Therapeutic advances in hematology·2026

Same author

GB2064 (lenumlostat) shows preliminary evidence of bone marrow collagen fibrosis reduction with manageable tolerability in JAK inhibitor-refractory myelofibrosis: results from the MYLOX-1 phase IIa study.

Haematologica·2026

Same journal

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026

Same journal

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026

Same journal

Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.

Blood·2026

Same journal

Decentralized Clinical Trials in Hematology: the Promise and the Peril.

Blood·2026

Same journal

How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.

Blood·2026

Same journal

The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design.

Blood·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 1, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Increasing therapeutic efficacy in MPN.

Claire N Harrison¹

¹GUY'S AND ST THOMAS' NHS FOUNDATION TRUST.

|March 29, 2014

Summary

This summary is machine-generated.

Deleting Janus kinase 2 (JAK2) in blood-forming cells prevents the start of myeloproliferative disease. This genetic change also significantly shrinks existing disease, offering new therapeutic strategies.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Experiment Videos

Last Updated: May 1, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Area of Science:

Hematology
Molecular Biology
Oncology

Background:

Myeloproliferative neoplasms (MPNs) are a group of cancers affecting blood cells.
Janus kinase 2 (JAK2) mutations are frequently implicated in MPNs.
Targeting key molecular pathways is crucial for MPN treatment.

Purpose of the Study:

To investigate the role of Janus kinase 2 (JAK2) in the initiation and progression of myeloproliferative disease.
To evaluate the therapeutic potential of JAK2 genetic deletion in established MPNs.

Main Methods:

Utilized genetic engineering techniques to delete JAK2 specifically within the hematopoietic system.
Developed and employed experimental models to induce and monitor myeloproliferative disease.
Assessed disease initiation, progression, and regression following JAK2 deletion.

Main Results:

Genetic deletion of JAK2 in hematopoietic cells effectively abrogated the initiation of myeloproliferative disease.
Substantial disease regression was observed when JAK2 was deleted after the onset of myeloproliferative disease.
Demonstrated the critical role of JAK2 signaling in MPN pathogenesis.

Conclusions:

JAK2 is essential for both the initiation and maintenance of myeloproliferative disease.
Targeted deletion of JAK2 presents a promising therapeutic strategy for MPNs.
These findings provide a strong rationale for developing JAK2-inhibiting therapies.